We found that knowing Ago2 protein levels in tumour improves the ability to predict breast cancer subtype (by 20%), which is related Ago2 staining improving the ability to predict Estrogen or Progesterone receptor status (by 15.7 and 17.5% respectively). This evidence concerns the gene PGR and neoplasm.